Captopril

Generic Name: Captopril

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₅NO_₃S

CAS Number: 62571-86-2

Unique Ingredient Identifier: 9G64RSX1XD

Background: Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.

Indication: For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial...

Associated Conditions: Aldosteronism, Anatomic renal artery stenosis, Congestive Heart Failure (CHF), Diabetic Nephropathy, Heart Failure, Hypertension, Hypertensive crisis, Non-STEMI Acute Coronary Syndrome, Raynaud's Phenomenon, Ejection fraction of 40% or less Left ventricular dysfunction

Associated Therapies: -

Clinical Trials

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

Phase 1

Withdrawn

Conditions: Healthy Volunteers

Interventions: Drug: Capoten
Drug: Captopril

First Posted Date: 2021-05-07

Last Posted Date: 2023-01-27

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT04878315

Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms

Phase 1

Withdrawn

Conditions: Bone Marrow Fibrosis
Myeloproliferative Neoplasm

Interventions: Drug: Captopril

First Posted Date: 2020-11-16

Last Posted Date: 2023-10-11

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT04629651

Locations: 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Atorvastatin
Drug: Captopril
Drug: L-carnitine

First Posted Date: 2018-09-06

Last Posted Date: 2019-06-17

Lead Sponsor: Tanta University

Target Recruit Count: 150

Registration Number: NCT03660293

Locations: 🇪🇬
Faculty of Medicine- Tanta University, Tanta, Gharbia, Egypt

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma

Interventions: Drug: Temozolomide
Drug: Aprepitant
Drug: Minocycline
Drug: Disulfiram
Drug: Celecoxib
Drug: Sertraline
Drug: Captopril
Drug: Itraconazole
Drug: Ritonavir
Drug: Auranofin

First Posted Date: 2016-05-12

Last Posted Date: 2021-10-05

Lead Sponsor: University of Ulm

Target Recruit Count: 10

Registration Number: NCT02770378

Locations: 🇩🇪
University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany

Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure

Phase 4

Completed

Conditions: Preeclampsia

Interventions: Drug: CLONIDINE
Drug: CAPTOPRIL

First Posted Date: 2013-01-07

Last Posted Date: 2013-07-29

Lead Sponsor: Instituto Materno Infantil Prof. Fernando Figueira

Target Recruit Count: 90

Registration Number: NCT01761916

Locations: 🇧🇷
IMIP, Recife, Pernambuco, Brazil

Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients

Phase 1

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Captopril
Drug: placebo

First Posted Date: 2012-06-22

Last Posted Date: 2019-08-01

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 24

Registration Number: NCT01626469

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Shigella Sonnei OSPC-rDT Conjugate Vaccine

Phase 1

Withdrawn

Conditions: Shigellosis

First Posted Date: 2011-07-21

Last Posted Date: 2017-07-02

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registration Number: NCT01399424

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

Phase 1

Terminated

Conditions: Hypertension
Pure Autonomic Failure
Multiple System Atrophy

Interventions: Drug: Losartan
Drug: Captopril
Drug: Placebo

First Posted Date: 2011-02-09

Last Posted Date: 2018-08-24

Lead Sponsor: Vanderbilt University

Target Recruit Count: 12

Registration Number: NCT01292694

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy

Conditions: Diabetes Mellitus
Arterial Hypertension

Interventions: Drug: Metformin
Drug: Glybenclamide
Drug: NPH insulin
Drug: Hydrochlorothiazide
Drug: Propranolol
Drug: Captopril
Drug: Amlodipine

First Posted Date: 2009-07-09

Last Posted Date: 2011-10-26

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 124

Registration Number: NCT00935805

Locations: 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Rapid Versus Prolonged Inpatient Up-Titration of Captopril

Phase 2

Conditions: Heart Disease

Interventions: Drug: Captopril

First Posted Date: 2008-08-27

Last Posted Date: 2008-08-27

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 50

Registration Number: NCT00742040

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy